{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T13:47:38Z","timestamp":1768312058885,"version":"3.49.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.ejphar.2007.01.052","type":"journal-article","created":{"date-parts":[[2007,2,5]],"date-time":"2007-02-05T12:27:05Z","timestamp":1170678425000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents"],"prefix":"10.1016","volume":"562","author":[{"given":"Lilach","family":"Steiner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galia","family":"Blum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Friedmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Levitzki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2007.01.052_bib1","first-page":"6237","article-title":"Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor","volume":"49","author":"Arteaga","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2007.01.052_bib2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1517\/14728222.9.4.753","article-title":"The insulin-like growth factor-I receptor as a target for cancer therapy","volume":"9","author":"Baserga","year":"2005","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejphar.2007.01.052_bib3","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ijc.11487","article-title":"The IGF-1 receptor in cancer biology","volume":"107","author":"Baserga","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2007.01.052_bib4","first-page":"3741","article-title":"Inhibitors of epidermal growth factor receptor kinase and of cyclin-dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of human papilloma virus 16-immortalized human keratinocytes","volume":"57","author":"Ben-Bassat","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2007.01.052_bib5","doi-asserted-by":"crossref","first-page":"15705","DOI":"10.1021\/bi001516y","article-title":"Substrate competitive inhibitors of IGF-1 receptor kinase","volume":"39","author":"Blum","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejphar.2007.01.052_bib6","doi-asserted-by":"crossref","first-page":"40442","DOI":"10.1074\/jbc.M305490200","article-title":"Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics","volume":"278","author":"Blum","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2007.01.052_bib7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0969-8051(01)00200-1","article-title":"Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase","volume":"28","author":"Bonasera","year":"2001","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejphar.2007.01.052_bib8","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0006-2952(00)00422-6","article-title":"Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy","volume":"60","author":"Brodt","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.01.052_bib9","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.2174\/092986705774454715","article-title":"The IGF-I\/IGF-I receptor pathway: implications in the pathophysiology of thyroid cancer","volume":"12","author":"Ciampolillo","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejphar.2007.01.052_bib10","first-page":"3264","article-title":"Protective effect of the insulin-like growth factor I receptor on apoptosis induced by okadaic acid","volume":"57","author":"D'Ambrosio","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2007.01.052_bib11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00384-005-0776-8","article-title":"The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence","volume":"21","author":"Davies","year":"2006","journal-title":"Int. J. Colorectal Dis."},{"key":"10.1016\/j.ejphar.2007.01.052_bib12","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1073\/pnas.97.7.3455","article-title":"Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice","volume":"97","author":"DiGiovanni","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2007.01.052_bib13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s003450100220","article-title":"Insulin-like growth factors and prostate cancer","volume":"19","author":"Djavan","year":"2001","journal-title":"World J. Urol."},{"key":"10.1016\/j.ejphar.2007.01.052_bib14","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/nsb721","article-title":"Structure and autoregulation of the insulin-like growth factor 1 receptor kinase","volume":"8","author":"Favelyukis","year":"2001","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.ejphar.2007.01.052_bib15","first-page":"961","article-title":"Antibody to type I insulinlike growth factor receptor inhibits growth of Wilms' tumor in culture and in athymic mice","volume":"135","author":"Gansler","year":"1989","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2007.01.052_bib16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt0206-127","article-title":"The second wave in kinase cancer drugs","volume":"24","author":"Garber","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejphar.2007.01.052_bib17","first-page":"1349","article-title":"Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells","volume":"1","author":"Hailey","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejphar.2007.01.052_bib18","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/0008-5472.CAN-05-1107","article-title":"In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I\/insulin receptor inhibitor, BMS-554417","volume":"66","author":"Haluska","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2007.01.052_bib19","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S1359-6446(05)03512-9","article-title":"Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer","volume":"10","author":"Hofmann","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejphar.2007.01.052_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0022-1759(00)00253-2","article-title":"Colorimetric determination of inhibition of hematopoietic progenitor cells in soft agar","volume":"244","author":"Horowitz","year":"2000","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ejphar.2007.01.052_bib21","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1093\/emboj\/16.18.5572","article-title":"Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog","volume":"16","author":"Hubbard","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.ejphar.2007.01.052_bib22","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/j.0022-202X.2004.22527.x","article-title":"Insulin-like growth factors (IGF) and IGF-binding proteins bound to vitronectin enhance keratinocyte protein synthesis and migration","volume":"122","author":"Hyde","year":"2004","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejphar.2007.01.052_bib23","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1210\/en.2001-211408","article-title":"Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling","volume":"143","author":"Kalli","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2007.01.052_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0014-5793(03)00069-3","article-title":"The pp60c-Src inhibitor PP1 is non-competitive against ATP","volume":"537","author":"Karni","year":"2003","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejphar.2007.01.052_bib25","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1158\/0008-5472.CAN-05-4239","article-title":"Insulin-like growth factor I secreted from prostate stromal cells mediates tumor-stromal cell interactions of prostate cancer","volume":"66","author":"Kawada","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2007.01.052_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1442-2042.1996.tb00628.x","article-title":"Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, and PC-3 cells","volume":"3","author":"Kimura","year":"1996","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.ejphar.2007.01.052_bib27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/sj.cgt.7700524","article-title":"Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer","volume":"10","author":"Lee","year":"2003","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ejphar.2007.01.052_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0304-3835(03)00159-9","article-title":"The insulin-like growth factor system and cancer","volume":"195","author":"LeRoith","year":"2003","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejphar.2007.01.052_bib29","series-title":"Signaling Networks and Cell Cycle Control: The Molecular Basis of Cancer and Other Diseases","first-page":"453","article-title":"Protein tyrosine kinase inhibitors as novel therapeutic agents","author":"Levitzki","year":"2000"},{"key":"10.1016\/j.ejphar.2007.01.052_bib30","first-page":"1","article-title":"Protein tyrosine kinase inhibitors as therapeutic agents","volume":"vol. 211","author":"Levitzki","year":"2000"},{"issue":"Suppl 1","key":"10.1016\/j.ejphar.2007.01.052_bib31","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0169-5002(03)00134-X","article-title":"EGF receptor as a therapeutic target","volume":"41","author":"Levitzki","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejphar.2007.01.052_bib32","first-page":"451","article-title":"Protein Kinase Inhibitors","volume":"vol. 1","author":"Levitzki","year":"2003"},{"key":"10.1016\/j.ejphar.2007.01.052_bib33","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1021\/ar0201207","article-title":"Protein kinase inhibitors as a therapeutic modality","volume":"36","author":"Levitzki","year":"2003","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejphar.2007.01.052_bib34","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev.biochem.75.103004.142657","article-title":"Tyrphostins and other tyrosine kinase inhibitors","volume":"75","author":"Levitzki","year":"2006","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejphar.2007.01.052_bib35","unstructured":"Litman, P., Ohne, O., Ben-Yaakov, S., Yechezkel, T., Salitra, Y., Rubnov, S., Cohen, I., Senderowitz, H., Kidron, D., Livnah, O., Levitzki, A., Livnah, N., in press. A novel substrate mimetic inhibitor of PKB\/Akt, inhibits prostate cancer tumor growth in mice by blocking the PKB pathway. Biochemistry (USA)."},{"key":"10.1016\/j.ejphar.2007.01.052_bib36","unstructured":"Livnah, N., Levitzki, A., Senderovitz, H., Yechezkel, T., Salitra, Y., Litman, P., Ohne, O., 2004. Cell Premeable Conjugates of Peptides for Inhibition of Protein Kinases. in: WO 2004\/110337 A2."},{"key":"10.1016\/j.ejphar.2007.01.052_bib37","first-page":"1006","article-title":"Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor","volume":"55","author":"Long","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2007.01.052_bib38","first-page":"5073","article-title":"An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation","volume":"63","author":"Maloney","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2007.01.052_bib39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ab.2006.07.029","article-title":"Extended silencing of the insulin-like growth factor-I receptor gene in MCF-7 cells by serial transfection with siRNA","volume":"357","author":"McVittie","year":"2006","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejphar.2007.01.052_bib40","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000150234","article-title":"Differential cooperation of a carcinogen with human papillomavirus type 6 and 16 DNAs in in vitro oncogenic transformation","volume":"33","author":"Mitrani-Rosenbaum","year":"1992","journal-title":"Intervirology"},{"key":"10.1016\/j.ejphar.2007.01.052_bib41","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1535-6108(04)00050-9","article-title":"Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors","volume":"5","author":"Mitsiades","year":"2004","journal-title":"Cancer Cells"},{"key":"10.1016\/j.ejphar.2007.01.052_bib42","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1385\/ENDO:22:3:293","article-title":"Inducible expression of dominant negative insulin-like growth factor I receptor in MCF-7 breast cancer cells","volume":"22","author":"Modha","year":"2003","journal-title":"Endocrine"},{"key":"10.1016\/j.ejphar.2007.01.052_bib43","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000066230","article-title":"The role of the IGF system in cancer: from basic to clinical studies and clinical applications","volume":"63","author":"Moschos","year":"2002","journal-title":"Oncology"},{"key":"10.1016\/j.ejphar.2007.01.052_bib44","first-page":"760","article-title":"Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines","volume":"60","author":"Nakamura","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2007.01.052_bib45","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1210\/endo.136.10.7664648","article-title":"Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid","volume":"136","author":"Neuenschwander","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2007.01.052_bib46","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1210\/en.2003-221028","article-title":"Insulin-like growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: possible mediators for the effects of diet and exercise on cancer cell survival","volume":"144","author":"Ngo","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2007.01.052_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0090-4295(01)01004-4","article-title":"Insulin-like growth factor I and prostate cancer","volume":"58","author":"O'Brien","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2007.01.052_bib48","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1182\/blood-2002-07-2307","article-title":"SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo","volume":"101","author":"O'Farrell","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2007.01.052_bib49","doi-asserted-by":"crossref","first-page":"39684","DOI":"10.1074\/jbc.M202766200","article-title":"Insulin\/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved","volume":"277","author":"Pandini","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2007.01.052_bib50","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.molmed.2004.12.005","article-title":"Novel insights into the implication of the IGF-1 network in prostate cancer","volume":"11","author":"Papatsoris","year":"2005","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejphar.2007.01.052_bib51","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1165\/rcmb.2004-0232OC","article-title":"The consequences of insulin-like growth factors\/receptors dysfunction in lung cancer","volume":"32","author":"Pavelic","year":"2005","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ejphar.2007.01.052_bib52","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrc1387","article-title":"Insulin-like growth factors and neoplasia","volume":"4","author":"Pollak","year":"2004","journal-title":"Nat. Rev., Cancer"},{"key":"10.1016\/j.ejphar.2007.01.052_bib53","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1046\/j.1365-2133.1999.03152.x","article-title":"Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors","volume":"141","author":"Powell","year":"1999","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejphar.2007.01.052_bib54","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1073\/pnas.91.6.2181","article-title":"Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant","volume":"91","author":"Prager","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2007.01.052_bib55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0165-4608(98)00064-8","article-title":"A Philadelphia-negative chronic myeloid leukemia with a BCR\/ABL fusion gene on chromosome 9","volume":"107","author":"Reddy","year":"1998","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.ejphar.2007.01.052_bib56","first-page":"1159","article-title":"Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer","volume":"58","author":"Resnik","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2007.01.052_bib57","first-page":"311","article-title":"Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity","volume":"73","author":"Rubin","year":"1995","journal-title":"Lab. Invest."},{"key":"10.1016\/j.ejphar.2007.01.052_bib58","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/1523-1747.ep12340934","article-title":"The role of IGF-I in human skin and its appendages: morphogen as well as mitogen?","volume":"109","author":"Rudman","year":"1997","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejphar.2007.01.052_bib59","first-page":"627","article-title":"A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I","volume":"63","author":"Sachdev","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2007.01.052_bib60","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/jnci\/94.13.972","article-title":"Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer","volume":"94","author":"Sandhu","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejphar.2007.01.052_bib61","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2141.2005.05579.x","article-title":"Autocrine\/paracrine involvement of insulin-like growth factor-I and its receptor in chronic lymphocytic leukaemia","volume":"130","author":"Schillaci","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejphar.2007.01.052_bib62","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1172\/JCI117441","article-title":"Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma","volume":"94","author":"Shapiro","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2007.01.052_bib63","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/1523-1747.ep12616668","article-title":"Expression of growth hormone receptor, insulin-like growth factor 1 (IGF-1) and IGF-1 receptor mRNA and proteins in human skin","volume":"99","author":"Tavakkol","year":"1992","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejphar.2007.01.052_bib64","doi-asserted-by":"crossref","first-page":"5828","DOI":"10.1073\/pnas.90.12.5828","article-title":"Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product","volume":"90","author":"Werner","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2007.01.052_bib65","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/mp.54.4.227","article-title":"The IGF\/IGFBP system in CNS malignancy","volume":"54","author":"Zumkeller","year":"2001","journal-title":"Mol. Pathol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299907000829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299907000829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T03:58:47Z","timestamp":1762142327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299907000829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":65,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0014299907000829"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2007.01.052","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2007.01.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}